



# Individuals with Scientific or Medical Training - Survey Feedback

**Purpose:** This document presents feedback submitted through the 2026 survey for individuals with scientific or medical training. The table reproduces the substantive survey information provided by respondents. Survey responses reflect the experience and opinions of individual respondents and have not been independently verified by PDAB. Blank survey items are shown as “No response.”

## Jardiance (empagliflozin)

|                                                                                                |                                                |
|------------------------------------------------------------------------------------------------|------------------------------------------------|
| Primary professional role                                                                      | Healthcare profession involved in patient care |
| Years of experience treating or studying this condition                                        | More than 10 years                             |
| Practice setting                                                                               | Outpatient clinic                              |
| Typical role of this drug treatment                                                            | First-line therapy                             |
| Patient population most commonly receiving this drug                                           | Moderate                                       |
| Is this drug clinically substitutable for at least one alternative?                            | Yes, for some patients                         |
| Compared to therapeutic alternatives, this drug provides                                       | Substantial additional clinical benefit        |
| Strength of evidence supporting use for its primary indication                                 | High (multiple RCTs, guideline-supported)      |
| Off-label use in your practice or system                                                       | Rare                                           |
| Utilization management requirement typically associated with this drug (Select all that apply) | Step therapy; Prior authorization              |
| Administrative burden relative to alternatives                                                 | Much higher                                    |
| Does utilization management delay patient access                                               | Frequently                                     |
| In your experience, patient out-of-pocket costs for this drug are                              | Significantly higher than alternatives         |



|                                                                                                                          |                            |
|--------------------------------------------------------------------------------------------------------------------------|----------------------------|
| <b>Have patients delayed or declined treatment due to cost?</b>                                                          | Frequently                 |
| <b>Impact of patient cost on adherence</b>                                                                               | Moderate impact            |
| <b>Are there other impacts that cause adherence issues?</b>                                                              | No response                |
| <b>Availability of the drug when clinically needed</b>                                                                   | Routinely available        |
| <b>If delays occur, primary cause</b>                                                                                    | No response                |
| <b>Overall impact of this drug on health system costs</b>                                                                | Increases costs moderately |
| <b>Overall value of this drug relative to its cost</b>                                                                   | High value                 |
| <b>From a clinical perspective, does this drug contribute to affordability concerns for patients?</b>                    | Yes                        |
| <b>Is there anything else you would like PDAB to know about this medication?</b>                                         | No response                |
| <b>If you could change one thing about how this prescription drug is priced or accessed in Oregon, what would it be?</b> | No response                |